IMVT vs. RYTM
IMVT (Immunovant, Inc.) and RYTM (Rhythm Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, IMVT returned 29.58%/yr vs 40.39%/yr for RYTM. At a 0.37 correlation, their price movements are largely independent.
Performance
IMVT vs. RYTM - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, IMVT achieves a 56.22% return, which is significantly higher than RYTM's 1.27% return.
IMVT
- 1D
- -3.36%
- 1M
- 18.11%
- 6M
- 52.55%
- YTD
- 56.22%
- 1Y
- 119.03%
- 3Y*
- 25.98%
- 5Y*
- 29.58%
- 10Y*
- —
RYTM
- 1D
- -6.13%
- 1M
- 22.65%
- 6M
- 7.31%
- YTD
- 1.27%
- 1Y
- 25.03%
- 3Y*
- 88.63%
- 5Y*
- 40.39%
- 10Y*
- —
IMVT vs. RYTM - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
IMVT Immunovant, Inc. | 56.22% | 2.62% | -41.21% | 137.35% | 108.33% | -81.55% | 191.05% | 11.37% |
RYTM Rhythm Pharmaceuticals, Inc. | 1.27% | 91.21% | 21.78% | 57.86% | 191.78% | -66.43% | 29.49% | -0.86% |
Correlation
The correlation between IMVT and RYTM is 0.35, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.35 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.36 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.38 |
Correlation (All Time) Calculated using the full available price history since Dec 19, 2019 | 0.37 |
Fundamentals
IMVT:
$8.15B
RYTM:
$7.44B
IMVT:
-$2.71
RYTM:
-$3.07
IMVT:
9.49
RYTM:
899.02
IMVT:
$0.00
RYTM:
$217.17M
IMVT:
-$206.00K
RYTM:
$194.16M
IMVT:
-$527.21M
RYTM:
-$182.86M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IMVT vs. RYTM — Risk / Return Rank
IMVT
RYTM
IMVT vs. RYTM - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Immunovant, Inc. (IMVT) and Rhythm Pharmaceuticals, Inc. (RYTM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| IMVT | RYTM | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.56 | ||
| Sortino ratioReturn per unit of downside risk | +2.35 | ||
| Omega ratioGain probability vs. loss probability | 1.37 | 1.12 | +0.25 |
| Calmar ratioReturn relative to maximum drawdown | 6.08 | 0.61 | +5.47 |
| Martin ratioReturn relative to average drawdown | 13.92 | 1.40 | +12.53 |
Loading charts...
Drawdowns
IMVT vs. RYTM - Drawdown Comparison
The maximum IMVT drawdown since its inception was -93.59%, roughly equal to the maximum RYTM drawdown of -92.10%. Use the drawdown chart below to compare losses from any high point for IMVT and RYTM.
Loading charts...
Drawdown Indicators
| IMVT | RYTM | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -93.59% | -92.10% | -1.49% |
Max Drawdown (1Y)Largest decline over 1 year | -20.98% | -35.54% | +14.56% |
Max Drawdown (3Y)Largest decline over 3 years | -69.88% | -35.54% | -34.34% |
Max Drawdown (5Y)Largest decline over 5 years | -69.88% | -84.42% | +14.54% |
Current DrawdownCurrent decline from peak | -24.66% | -7.84% | -16.82% |
Average DrawdownAverage peak-to-trough decline | -53.63% | -31.97% | -21.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.15% | 15.62% | -6.47% |
Volatility
IMVT vs. RYTM - Volatility Comparison
The current volatility for Immunovant, Inc. (IMVT) is 11.34%, while Rhythm Pharmaceuticals, Inc. (RYTM) has a volatility of 12.49%. This indicates that IMVT experiences smaller price fluctuations and is considered to be less risky than RYTM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| IMVT | RYTM | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.34% | 12.49% | -1.15% |
Volatility (6M)Calculated over the trailing 6-month period | 44.69% | 35.73% | +8.96% |
Volatility (1Y)Calculated over the trailing 1-year period | 62.47% | 45.15% | +17.32% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 74.81% | 76.38% | -1.57% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 78.00% | 71.40% | +6.60% |
Dividends
IMVT vs. RYTM - Dividend Comparison
Neither IMVT nor RYTM has paid dividends to shareholders.
Financials
IMVT vs. RYTM - Financials Comparison
This section allows you to compare key financial metrics between Immunovant, Inc. and Rhythm Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
IMVT and RYTM have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RYTM has higher volatility (12.49%) compared to IMVT (11.34%). In terms of maximum drawdown, IMVT dropped -93.59% vs RYTM's -92.10%.
IMVT currently has the higher Sharpe Ratio (2.04 vs 0.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for IMVT and RYTM
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer